TONMYA Drug Patent Profile

Which patents cover Tonmya, and what generic alternatives are available?

Tonmya is a drug marketed by Tonix and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries.

The generic ingredient in TONMYA is cyclobenzaprine hydrochloride. There are sixteen drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the cyclobenzaprine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tonmya

A generic version of TONMYA was approved as cyclobenzaprine hydrochloride by ACTAVIS LABS FL INC on May 3^rd, 1989.

Summary for TONMYA

International Patents:	53
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Patent Applications:	1,449
Drug Prices:	Drug price information for TONMYA
What excipients (inactive ingredients) are in TONMYA?	TONMYA excipients list
DailyMed Link:	TONMYA at DailyMed

See drug prices for TONMYA

Recent Clinical Trials for TONMYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tonix Pharmaceuticals, Inc.	Phase 3

See all TONMYA clinical trials

Pharmacology for TONMYA

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

US Patents and Regulatory Information for TONMYA

TONMYA is protected by four US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes			Y
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes			Y
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes			Y
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes			Y
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428-001	Aug 15, 2025		RX	Yes	Yes

International Patents for TONMYA

See the table below for patents covering TONMYA around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	196014
Malaysia	196014	EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE
China	110152005
New Zealand	747040	Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
Cyprus	1122740

TONMYA Market Analysis and Financial Projection

Last updated: May 5, 2026

TONMYA: Market dynamics and financial trajectory

What is TONMYA and where does it sit in the market

TONMYA is a brand name for rosuvastatin calcium (marketed to lower LDL cholesterol and reduce cardiovascular risk in appropriate patient populations). It competes in the statins segment, which is mature, highly price-disciplined, and dominated by multiple multisource generics plus entrenched originators in major markets.

Market structure for statins

• High generic penetration: Statins are among the most heavily genericized therapeutic classes.
• Low differentiation beyond formulation and supply reliability: Clinical endpoints are largely class-consistent; competitive advantage often comes from pricing, contracting, and access.
• Tight payer controls: Formulary placement is frequently optimized through step therapy, preferred-tier pricing, rebates, and pharmacy benefit manager (PBM) economics rather than novel pharmacology.

How does TONMYA typically win or lose in statin competition

In mature statin markets, brand or niche-branded products generally face four recurring commercial constraints:

1. Average Selling Price (ASP) pressure

   • Generic competitors anchor pricing.
   • Price increases tend to be limited by plan design and reference pricing (where applicable).

2. Formulary placement and rebate dynamics

   • Access is driven by net price after rebates, not list price.
   • PBMs tend to steer patients toward preferred statins unless the product earns favorable net pricing.

3. Switching friction

   • Even when prescribers accept a new statin, patient-level switching requires clinical justification and ongoing adherence support.
   • Pharmacovigilance and tolerability issues (class side effects) can slow conversion from existing therapy.

4. Supply and manufacturing economics

   • For small brands, uninterrupted supply and cost-of-goods control are decisive.
   • Any production disruption can quickly move patients and prescribers to alternatives.

What do the core market dynamics imply for TONMYA volumes

Because TONMYA sits inside a crowded statins category, its volume trajectory depends less on “market growth” and more on share capture through contracting and patient access:

• Volume upside is primarily share-driven. The overall statins category grows modestly, but incremental patients often displace existing statins.
• Trade-down risk is persistent. If plan contracts change or a competitor undercuts net pricing, TONMYA volumes can decline.
• Seasonality is modest. Chronic lipid-lowering typically reduces sharp seasonal swings, but insurance renewals and formulary cycles can create step changes.

---

What is the financial trajectory profile for TONMYA

In mature genericized therapeutic segments, financial trajectories typically follow a predictable pattern:

1) Launch or relaunch phase: access build

• Revenue growth is often constrained by:
  • formulary adoption timelines,
  • rebate negotiations,
  • pharmacy channel onboarding,
  • and prescriber familiarity.

Net effect: Early revenue tends to track contracting progress rather than broad market awareness.

2) Mid-term phase: margin compression or stabilization

Once contracting matures:

• If TONMYA secures preferred status in managed care, net revenue can stabilize even if list prices fall.
• If it remains non-preferred, revenue can stagnate as generics capture demand.

Net effect: profitability tends to move with net price and channel mix.

3) Late phase: competitive and policy pressure

With multiple equivalents available:

• payer reference pricing can compress net realizations,
• competitors can introduce new package/strength strategies,
• and plan formularies update every cycle.

Net effect: declining net ASP is a baseline risk unless TONMYA holds differentiated access.

---

How to read TONMYA’s financial health using statin economics

A practical approach for assessing TONMYA’s financial trajectory in the statins segment uses the following indicators:

Revenue

• Look for revenue growth that correlates with formulary wins and channel expansion.
• Expect limited growth independent of contracting.

Gross margin

• Track whether the product maintains stable COGS and can absorb rebate pressure.
• If competitors cut aggressively, the product may show falling gross margin before revenue also falls.

Net pricing

• Persistent net ASP decreases often precede volume declines.
• Rebates can mask list price declines, so net ASP is the more important signal.

Market share

• Share changes can be driven by:
  • plan placement,
  • switching from other statins due to intolerance or supply,
  • and prescriber prescribing behavior.

---

Competitive landscape and likely impact on pricing

What competitors dominate where TONMYA is sold

Statins competition typically includes:

• originator or long-standing brands (where still branded),
• high-volume generics across multiple strengths and package sizes,
• and alternative statins (rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin).

Commercial implication: TONMYA must compete against products that offer a combination of low net price and high payer acceptance.

What that does to TONMYA

• Net price floor: contracts set a minimum sustainable net price, below which the product cannot profitably hold volume.
• Contract renewal risk: net realizations are reset during renewals, which can produce revenue volatility.
• Channel concentration: if TONMYA lands with a few large distributors and PBMs, performance can swing with contract renegotiations.

---

Key risks to the financial trajectory

1. Net ASP compression

   • Generic reference pricing and PBM pressure reduce net realized pricing.

2. Formulary downgrades

   • A move from preferred to non-preferred tier often causes immediate share erosion.

3. Supply continuity

   • Manufacturing or regulatory issues can abruptly reduce availability and patient continuity.

4. Patient adherence

   • Statins are taken long term; adherence can be stable, but switching friction can slow retention.

5. Regulatory and labeling updates

   • Changes in guidance that affect prescribing patterns can shift volume between statins.

---

Key Takeaways

• TONMYA’s market position is constrained by the mature, generic-heavy statins category, where growth is mainly share-driven and financial performance is contracting- and net-price dependent.
• Its financial trajectory typically follows a pattern: access build, then profitability stabilization or margin compression, then renewal-driven pressure unless it holds preferred payer placement.
• The most actionable read-through for TONMYA’s financial health is net ASP plus share, since list price often diverges from realized revenue due to rebate and PBM mechanics.

---

FAQs

1. What drives TONMYA revenue in statins?
   Formulary access, preferred-tier placement, rebate outcomes, and patient share shifts from other statins.

2. Is pricing power realistic for TONMYA?
   Typically limited. Generic competition and payer reference pricing cap net price outcomes.

3. What metric best indicates TONMYA’s financial trajectory?
   Net realized pricing (net ASP) and the resulting market share trend.

4. What usually causes revenue volatility for statin brands?
   PBM and insurer contract renewals, formulary tier changes, and distributor or supply disruptions.

5. How does TONMYA compete beyond clinical value?
   Through net price positioning, supply reliability, package/strength strategy, and payer contracting.

---

References

[1] Bloomberg Drug Database (industry and market references for pharmaceutical products and brand-level market context).
[2] FDA Orange Book (drug substance/approval and reference context for statin products).
[3] IQVIA Institute for Human Data Science and industry reporting on generic penetration and managed care dynamics in chronic therapies.